Axial Spondyloarthritis (axSpA) Pipeline Summary

DelveInsight’s, “Axial Spondyloarthritis (axSpA) - Pipeline Insight, 2026” report provides comprehensive insights about 28+ companies and 30+ pipeline drugs in Axial Spondyloarthritis (axSpA) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Axial Spondyloarthritis (axSpA): Understanding

Axial Spondyloarthritis (axSpA): Overview

Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease that predominantly affects the axial skeleton, particularly the sacroiliac joints and spine. It encompasses both radiographic axSpA (ankylosing spondylitis) and non-radiographic axSpA, which may not show definitive structural changes on conventional radiographs. Chronic back pain and spinal stiffness are the most common presenting features, while peripheral musculoskeletal manifestations and extra-musculoskeletal manifestations, including uveitis, psoriasis, and inflammatory bowel disease, may also occur. Persistent disease activity can result in irreversible structural damage, impaired physical function, and reduced quality of life.

The exact cause of axSpA is not completely established and is considered multifactorial, involving genetic susceptibility and environmental or immune-mediated factors. HLA-B27 is the most consistently recognized genetic association, although axSpA can also occur in HLA-B27-negative individuals. A family history of spondyloarthritis and the presence of associated conditions such as psoriasis or inflammatory bowel disease may increase the likelihood of disease. Immune pathways involving tumor necrosis factor (TNF) and the interleukin (IL)-23/IL-17 axis have also been implicated in disease development and progression.

The pathophysiology of axSpA involves chronic inflammation at the axial skeleton, particularly at the entheses and sacroiliac joints, followed by structural changes that can lead to new bone formation and spinal ankylosis. The disease is associated with inflammatory signaling involving TNF and the IL-23/IL-17 pathway, which contributes to inflammation at characteristic skeletal and extra-articular sites. Sustained inflammation can result in structural damage, including syndesmophyte formation and progressive fusion of the spine in some patients. The involvement of these inflammatory pathways also helps explain the occurrence of extra-musculoskeletal manifestations such as uveitis, psoriasis, and inflammatory bowel disease.

Diagnosis of axSpA is based on an overall assessment of the patient's clinical presentation, laboratory findings, and imaging features, rather than a single diagnostic test. Chronic inflammatory back pain, particularly when associated with young age at onset, spinal stiffness, improvement with exercise, or a favorable response to NSAIDs, may raise clinical suspicion. Laboratory evaluation may include inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) and HLA-B27 testing. Imaging of the sacroiliac joints and spine is important; conventional radiography can identify structural changes, while MRI can detect active inflammation before definitive radiographic abnormalities develop, supporting recognition of non-radiographic axSpA.

Management of axSpA involves both non-pharmacological and pharmacological approaches, with treatment aimed at controlling symptoms and inflammation, maintaining physical function, and preventing structural progression. Physiotherapy, regular exercise, and physical activity form an important component of management. NSAIDs are generally used as the first-line pharmacological treatment. For patients with persistent active disease despite conventional treatment, biologic therapies such as TNF inhibitors and IL-17 inhibitors may be used.

"Axial Spondyloarthritis (axSpA)- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Axial Spondyloarthritis (axSpA) pipeline landscape is provided which includes the disease overview and Axial Spondyloarthritis (axSpA) treatment guidelines. The assessment part of the report embraces, in depth Axial Spondyloarthritis (axSpA) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Axial Spondyloarthritis (axSpA) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Axial Spondyloarthritis (axSpA) R&D. The therapies under development are focused on novel approaches to treat/improve Axial Spondyloarthritis (axSpA).

Axial Spondyloarthritis (axSpA) Emerging Drugs Chapters

This segment of the Axial Spondyloarthritis (axSpA) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Axial Spondyloarthritis (axSpA) Emerging Drugs

• Zemprocitinib (LNK01001): Lynk Pharmaceuticals/Simcere Pharmaceuticals

LNK01001 is an investigational, oral small-molecule Janus kinase 1 (JAK1) inhibitor developed by Lynk Pharmaceuticals for the treatment of ankylosing spondylitis (AS), a form of axial spondyloarthritis. By selectively inhibiting JAK1, LNK01001 is designed to interfere with JAK-STAT signaling, an intracellular pathway used by multiple cytokines involved in inflammatory and immune responses. Inhibition of JAK1 therefore reduces downstream cytokine signaling and the expression of inflammatory mediators, with the potential to decrease inflammation, pain, and stiffness associated with AS. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of of ankylosing spondylitis which is a specific, radiographic form of axial spondyloarthritis.

• VC005: Jiangsu Vcare Pharmatech/ Huadong Medicine

VC005 Tablets is a novel, potent, and highly selective second-generation JAK1 inhibitor, for which Jiangsu Vcare holds independent intellectual property rights. In August 2025, Jiangsu Vcare entered into an exclusive strategic cooperation with Huadong Medicine regarding the commercialization rights of VC005 Tablets in Mainland China. By selectively inhibiting JAK1, VC005 Tablets reduces inflammatory responses and the activation of immune cells. While maintaining strong JAK1 inhibitory activity, VC005 Tablets further reduces JAK2 inhibitory activity in a selective manner (based on in vitro kinase assay results), which is expected to alleviate safety issues caused by excessive JAK2 inhibition in clinical practice. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of ankylosing spondylitis which is a specific, radiographic form of axial spondyloarthritis.

• GRWD0715: Greywolf Therapeutics

GRWD0715 is an investigational, first-in-class, oral small-molecule inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1). ERAP1 is an antigen-processing enzyme that trims peptides before their presentation on the cell surface by major histocompatibility complex class I (MHC-I) molecules. In axSpA, the company hypothesizes that ERAP1-mediated processing contributes to the generation and presentation of disease-relevant self-peptides that are incorrectly recognized by T cells, leading to an autoimmune response. GRWD0715 is designed to inhibit ERAP1 and thereby alter the antigen repertoire presented at the cell surface, preventing presentation of the pathogenic self-peptide and reducing activation of autoreactive CD8+ T cells and downstream inflammatory responses. Thus, rather than broadly suppressing immune activity, GRWD0715 is intended to intervene upstream at the antigen-processing and presentation pathway, targeting a potential source of the autoimmune response in axSpA. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Axial Spondyloarthritis (axSpA).

• DB015: DotBio

DB015 is an investigational bispecific antibody being developed by DotBio for ankylosing spondylitis (AS). DB015 is an IL-17-based bispecific antibody. By targeting the IL-17 pathway, DB015 is designed to interfere with IL-17-mediated inflammatory signaling, thereby reducing downstream inflammatory responses involved in disease activity. Currently, the drug is being evaluated in the Preclinical stage of its development for the treatment of ankylosing spondylitis which is a specific, radiographic form of axial spondyloarthritis.

Further product details are provided in the report……..

Axial Spondyloarthritis (axSpA): Therapeutic Assessment

This segment of the report provides insights about the different Axial Spondyloarthritis (axSpA) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Axial Spondyloarthritis (axSpA)

There are approx. 28+ key companies which are developing the therapies Axial Spondyloarthritis (axSpA). The companies which have their Axial Spondyloarthritis (axSpA) drug candidates in the most advanced stage, i.e. Phase III include, Lynk Pharmaceuticals and others.

• Phases

DelveInsight’s report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Axial Spondyloarthritis (axSpA) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Axial Spondyloarthritis (axSpA): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Axial Spondyloarthritis (axSpA) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Axial Spondyloarthritis (axSpA) drugs.

Axial Spondyloarthritis (axSpA) Report Insights

• Axial Spondyloarthritis (axSpA) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Axial Spondyloarthritis (axSpA) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Axial Spondyloarthritis (axSpA) drugs?
• How many Axial Spondyloarthritis (axSpA) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Axial Spondyloarthritis (axSpA)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Axial Spondyloarthritis (axSpA) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Axial Spondyloarthritis (axSpA) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Lynk Pharmaceuticals
• Simcere Pharmaceuticals
• Jiangsu Vcare Pharmatech
• Huadong Medicine
• Greywolf Therapeutics
• DotBio
• XBiotech USA
• Merck Sharp & Dohme LLC
• Spyre Therapeutics Inc.
• Alfasigma
• Moonlake Immunotherapeutics
• Hillstar Bio

Key Products

• Zemprocitinib (LNK01001)
• VC005
• GRWD0715
• DB015
• Vilamakitug
• Tulisokibart
• SPY072
• Filgotinib
• Sonelokimab
• HSB-101